First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison
| العنوان: | First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison |
|---|---|
| المؤلفون: | Taramasso, L., Biagio, Di, Maggiolo, A., Tavelli, F., Lo Caputo, A., Bonora, S., Zaccarelli, S., Caramello, M., Costantini, P., Viscoli, A., D'Arminio, Monforte, Cozzi-Lepri, A., Andreoni, A., Angarano, M., Antinori, G., Castelli, A., Cauda, F., Perri, Di, Galli, G., Iardino, M., Ippolito, R., Lazzarin, G., Perno, A., C. F., Von, Schloesser, Viale, F., Castagna, P., Ceccherini-Silberstein, A., Girardi, F., Mussini, E., Puoti, C., Ammassari, M., Balotta, A., Bandera, C., Bonfanti, A, Borderi, P., Calcagno, M., Calza, A., Capobianchi, L., Cingolani, M. R., Cinque, A., Luca, De, Gianotti, A., Gori, N., Guaraldi, A., Lapadula, G., Lichtner, G., Madeddu, M., Marchetti, G., Marcotullio, G., Monno, S., Nozza, L., Quiros, Roldan, Rossotti, E., Rusconi, R., Santoro, S., Saracino, M. M., Fanti, A., Galli, I., Lorenzini, L, Rodano, P., Shanyinde, A., Carletti, M., Carrara, F., Caro, Di, Graziano, S., Petrone, F., Prota, G, Quartu, S., Truffa, S., Giacometti, A., Valeriani, C., Santoro, C., Suardi, C., Donati, V., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., Manconi, P. E., Piano, P., Cacopardo, B., Celesia, B., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Mazzotta, F., Vichi, F., Cassola, G., Alessandrini, A., Bobbio, N., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, A. P., Rizzardini, G., Ridolfo, A. L., Piolini, R., Salpietro, S., Carenzi, L., Moioli, M. C., Tincati, C., Puzzolante, C., Abrescia, N., Chirianni, A., Borgia, G., Di Martino, F., Maddaloni, L., Gentile, I., Orlando, R., Baldelli, F., Francisci, D., Parruti, G., Ursini, T., Magnani, G., Ursitti, M. A., Vullo, V., Cristaudo, A., Baldin, G., Cicalini, S., Gallo, L., Nicastri, E., Acinapura, R., Capozzi, M., Libertone, R., Savinelli, S., Latini, A., Cecchetto, M., Viviani, F., Mura, M. S., Rossetti, B., Orofino, G. C., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V. |
| المساهمون: | Taramasso, L, Di Biagio, A, Maggiolo, F, Tavelli, A, Lo Caputo, S, Bonora, S., Zaccarelli, M, Caramello, P, Costantini, A, Viscoli, C., d'Arminio Monforte, A, Cozzi-Lepri, A, on behalf of the Italian Cohort NaiveAntiretrovirals (ICONA) Foundation Study, Group, Castagna, A, Taramasso, L., Di Biagio, A., Maggiolo, F., Tavelli, A., Lo Caputo, S., Zaccarelli, M., Caramello, P., Costantini, A., d'Arminio Monforte, A., Cozzi-Lepri, A., Andreoni, M., Angarano, G., Antinori, A., Castelli, F., Cauda, R., Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Perno, C.F., von Schloesser, F., Viale, P., Castagna, A., Ceccherini-Silberstein, F., Girardi, E., Mussini, C., Puoti, M., Ammassari, A., Balotta, C., Bandera, A., Bonfanti, P., Borderi, M., Calcagno, A., Calza, L., Capobianchi, M.R., Cingolani, A., Cinque, P., De Luca, A., Gianotti, N., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Marchetti, G., Marcotullio, S., Monno, L., Nozza, S., Quiros Roldan, E., Rossotti, R., Rusconi, S., Santoro, M.M., Saracino, A., Fanti, I., Galli, L., Lorenzini, P., Rodano, A., Shanyinde, M., Carletti, F., Carrara, S., Di Caro, A., Graziano, S., Petrone, F., Prota, G., Quartu, S., Truffa, S., Giacometti, A., Valeriani, C., Santoro, C., Suardi, C., Donati, V., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., Manconi, P.E., Piano, P., Cacopardo, B., Celesia, B., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Mazzotta, F., Vichi, F., Cassola, G., Alessandrini, A., Bobbio, N., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, A.P., Rizzardini, G., Ridolfo, A.L., Piolini, R., Salpietro, S., Carenzi, L., Moioli, M.C., Tincati, C., Puzzolante, C., Abrescia, N., Chirianni, A., Borgia, G., Di Martino, F., Maddaloni, L., Gentile, I., Orlando, R., Baldelli, F., Francisci, D., Parruti, G., Ursini, T., Magnani, G., Ursitti, M.A., Vullo, V., Cristaudo, A., Baldin, G., Cicalini, S., Gallo, L., Nicastri, E., Acinapura, R., Capozzi, M., Libertone, R., Savinelli, S., Latini, A., Cecchetto, M., Viviani, F., Mura, M.S., Rossetti, B., Orofino, G.C., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V., Bonora, S, Viscoli, C, Andreoni, M, Angarano, G, Antinori, A, Castelli, F, Cauda, R, Di Perri, G, Galli, M, Iardino, R, Ippolito, G, Lazzarin, A, Perno, C, von Schloesser, F, Viale, P, Ceccherini-Silberstein, F, Girardi, E, Mussini, C, Puoti, M, Ammassari, A, Balotta, C, Bandera, A, Bonfanti, P, Borderi, M, Calcagno, A, Calza, L, Capobianchi, M, Cingolani, A, Cinque, P, De Luca, A, Gianotti, N, Gori, A, Guaraldi, G, Lapadula, G, Lichtner, M, Madeddu, G, Marchetti, G, Marcotullio, S, Monno, L, Nozza, S, Quiros Roldan, E, Rossotti, R, Rusconi, S, Santoro, M, Saracino, A, Fanti, I, Galli, L, Lorenzini, P, Rodano, A, Shanyinde, M, Carletti, F, Carrara, S, Di Caro, A, Graziano, S, Petrone, F, Prota, G, Quartu, S, Truffa, S, Giacometti, A, Valeriani, C, Santoro, C, Suardi, C, Donati, V, Verucchi, G, Minardi, C, Quirino, T, Abeli, C, Manconi, P, Piano, P, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Sighinolfi, L, Segala, D, Mazzotta, F, Vichi, F, Cassola, G, Alessandrini, A, Bobbio, N, Mazzarello, G, Mastroianni, C, Belvisi, V, Caramma, I, Chiodera, A, Castelli, A, Rizzardini, G, Ridolfo, A, Piolini, R, Salpietro, S, Carenzi, L, Moioli, M, Tincati, C, Puzzolante, C, Abrescia, N, Chirianni, A, Borgia, G, Di Martino, F, Maddaloni, L, Gentile, I, Orlando, R, Baldelli, F, Francisci, D, Parruti, G, Ursini, T, Magnani, G, Ursitti, M, Vullo, V, Cristaudo, A, Baldin, G, Cicalini, S, Gallo, L, Nicastri, E, Acinapura, R, Capozzi, M, Libertone, R, Savinelli, S, Latini, A, Cecchetto, M, Viviani, F, Mura, M, Rossetti, B, Orofino, G, Sciandra, M, Bassetti, M, Londero, A, Pellizzer, G, Manfrin, V, Perno, C. F., Capobianchi, M. R., Santoro, M. M., Manconi, P. E., Castelli, A. P., Ridolfo, A. L., Moioli, M. C., Ursitti, M. A., Mura, M. S., Orofino, G. C. |
| المصدر: | HIV medicine. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | 0301 basic medicine, medicine.medical_specialty, Efavirenz, combination antiretroviral therapy, durability, efavirenz, naïve, rilpivirine, Health Policy, Infectious Diseases, Pharmacology (medical), Infectious Disease, Emtricitabine, Gastroenterology, NO, 03 medical and health sciences, chemistry.chemical_compound, Interquartile range, Internal medicine, medicine, business.industry, 030112 virology, Confidence interval, Discontinuation, naive, Regimen, chemistry, combination antiretroviral therapy, durability, efavirenz, naïve, rilpivirine, Rilpivirine, business, Viral load, medicine.drug |
| الوصف: | Objectives: The aim of this study was to compare the durabilities of efavirenz (EFV) and rilpivirine (RPV) in combination with tenofovir/emtricitabine (TDF/FTC) in first-line regimens. Methods: A multicentre prospective and observational study was carried out. We included all patients participating in the Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study who started first-line combination antiretroviral therapy (cART) with TDF/FTC in combination with RPV or EFV, with a baseline viral load < 100 000 HIV-1 RNA copies/mL. Survival analyses using Kaplan–Meier (KM) curves and Cox regression with time-fixed covariates at baseline were employed. Results: Overall, 1490 ART-naïve patients were included in the study, of whom 704 were initiating their first cART with EFV and 786 with RPV. Patients treated with EFV, compared with those on RPV, were older [median 36 (interquartile range (IQR) 30–43) years vs. 33 (IQR 27–39) years, respectively; P < 0.001], were more frequently at Centers for Disease Control and Prevention (CDC) stage C (3.1% vs. 1.4%, respectively; P = 0.024), and had a lower median baseline CD4 count [340 (IQR 257–421) cells/μL vs. 447 (IQR 347–580) cells/μL, respectively; P < 0.001] and a higher median viral load [4.38 (IQR 3.92–4.74) log10 copies/mL vs. 4.23 (IQR 3.81–4.59) log10 copies/mL, respectively], (P = 0.004). A total of 343 patients discontinued at least one drug of those included in the first cART regimen, more often EFV (26%) than RPV (13%), by 2 years (P < 0.0001). After adjustment, patients treated with EFV were more likely to discontinue at least one drug for any cause [relative hazard (RH) 4.09; 95% confidence interval (CI) 2.89–5.80], for toxicity (RH 2.23; 95% CI 1.05–4.73) for intolerance (RH 5.17; 95% CI 2.66–10.07) and for proactive switch (RH 10.96; 95% CI 3.17–37.87) than those starting RPV. Conclusions: In our nonrandomized comparison, RPV was better tolerated, less toxic and showed longer durability than EFV, without a significant difference in rates of discontinuation because of failures. |
| وصف الملف: | STAMPA |
| تدمد: | 1468-1293 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a12fec8c3d3c5e0e2c1f37fa4403b86Test https://pubmed.ncbi.nlm.nih.gov/29846042Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....9a12fec8c3d3c5e0e2c1f37fa4403b86 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14681293 |
|---|